Evidence map›Paper›PMID 41678328›Full record

GuidelineJournal of the European Academy of Dermatology and Venereology : JEADV2026

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

A Nanda, B Tedbirt, C Bodemer, M C Bolling, M El Hachem, M Nikolić, E Benton, M Caproni, D De, D Didona and 22 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Guideline
  2. Bridging the gap between the clinical need and drug approval in paediatric auto immune blistering diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

A NandaAs'ad Al-Hamad Dermatology Center, Kuwait City, Kuwait.ORCID https://orcid.org/0000-0002-1223-3181
B TedbirtDepartment of Dermatology, French Reference Center for Auto Immune Blistering Diseases, Rouen University Hospital, Normandie University, Rouen, France.
C BodemerUniv Rouen Normandie, Inserm, Normandie Univ, PANTHER UMR 1234, Rouen, France.
M C BollingDepartment of Dermatology, Centers of Expertise for Blistering Diseases and European Reference Network for Rare Skin Diseases (ERN SKIN), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
M El HachemDermatology Unit and Genodermatosis Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
M NikolićDivision of Pediatric Dermatology, Department of Dermatology and Venereology, University of Belgrade School of Medicine, Belgrade, Serbia.
E BentonSt John's Institute of Dermatology, Guy's & St Thomas' NHS Trust, London, UK.
M CaproniDepartment of Health Sciences, Rare Skin Diseases Unit, P.O. Piero Palagi, Azienda USL Toscana Centro, ERN-SKIN Member, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-7471-3471
D DeDepartment of Dermatology, Venereology and Leprology, Postgarduate Institute of Medical Education and Research, Chandigarh, India.
D DidonaDepartment of Dermatology, Rare Skin Diseases Center, Istituto Dermopatico dell'immacolata, IDI-IRCCS, Rome, Italy.
K DrenovskaDepartment of Dermatology and Venereology, Medical Faculty, Medical University - Sofia, Sofia, Bulgaria.ORCID https://orcid.org/0000-0002-8254-1630
M GoebelerDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Wurzburg, Germany.
M HertlDepartment of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.
B HorváthDepartment of Dermatology, Centers of Expertise for Blistering Diseases and European Reference Network for Rare Skin Diseases (ERN SKIN), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
M KasperkiewiczDivision of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
D KiritsiFirst Department of Dermatology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
M LarraldeDepartment of Dermatology Hospital Alemán, Buenos Aires, Argentina.
A V MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-8160-4169
J MeijerDepartment of Dermatology, Centers of Expertise for Blistering Diseases and European Reference Network for Rare Skin Diseases (ERN SKIN), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-7654-3528
D F MurrellDepartment of Dermatology, St George Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-2971-0199
J PowellDivision of Dermatology, Department of Paediatrics, CHU Ste-Justine, Universite de Montreal, Montreal, Quebec, Canada.
E SprecherDivision of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.ORCID https://orcid.org/0000-0002-4093-1032
N S ChandranDivision of Dermatology, Department of Medicine, National University Hospital, Singapore City, Singapore.
M M TomaykoDepartment of Dermatology and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
S UzunDepartment of Dermatology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
N van BeekDepartment of Dermatology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lubeck, Germany.ORCID https://orcid.org/0000-0002-3265-0011
H OttSection of Pediatric Dermatology, Munich University Center for Children with Medical and Developmental Complexity, Ludwig-Maximilians-University Hospital, Munich, Germany.
A Patsatsi2nd Dermatology Department, Aristotle University School of Medicine, AIBD Center of Expertise, Papageorgiou General Hospital, Thessaloniki, Greece.ORCID https://orcid.org/0000-0001-9616-2001
A TorreloDepartment of Dermatology, Hospital Infantil Niño Jesús, Madrid, Spain.
A Welfringer-MorinDepartment of Dermatology, French Center of Competence for Auto Immune Blistering Diseases, Necker-Enfants Malades Hospital, Paris, France.ORCID https://orcid.org/0000-0001-7479-3689
E SchmidtDepartment of Dermatology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lubeck, Germany.ORCID https://orcid.org/0000-0002-1206-8913
P JolyDepartment of Dermatology, French Reference Center for Auto Immune Blistering Diseases, Rouen University Hospital, Normandie University, Rouen, France.ORCID https://orcid.org/0000-0002-5734-0255

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutoimmune blistering diseases (AIBDs) in children and adolescents present a major challenge in diagnosis and management because of their rarity and the presence of other differential diagnoses with blistering. They are potentially serious, and timely diagnosis and optimal management can help prevent morbidity related to both the diseases and their treatments.

methodsThe Autoimmune Blistering Diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated evidence-based, expert-informed clinical guidelines for the diagnosis, treatment and monitoring of paediatric AIBDs. A writing group conducted a systematic review of the available literature on AIBDs in children and adolescents, and since there is limited strong evidence in the literature, recommendations were formulated by consensus over three rounds of structured feedback and revision by the Core Group and Expert Group of the task force (32 voting experts; >75% agreement threshold).

resultsAlthough all AIBDs-including intra-epidermal and subepidermal blistering disorders-are reported in children, linear IgA dermatosis (LAD) is the most common (42-83%). The diagnostic approach in the paediatric age group does not differ from that in adults. Treatment recommendations are tailored to paediatric patients, taking into account developmental pharmacokinetics, potential adverse effects and the impact of disease and therapy on quality of life.

conclusionsThese guidelines provide the first comprehensive, paediatric-focused framework for the diagnosis and management of AIBDs. Implementing the recommendations should harmonize care, reduce treatment-related toxicity and improve quality of life for affected children while steering future research towards critical knowledge gaps.

Indexed as

Autoimmune DiseasesBlisterSkin Diseases, VesiculobullousAdolescentChildEuropeHumansLinear IgA Bullous Dermatosisdermatitis herpetiformisepidermolysis bullosa acquisitalinear IgA diseasemucous membrane pemphigoidpaediatricspemphigoidpemphigus

Identifiers

PMID41678328
PMCPMC13308672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.